IL2 and neoplasm: The addition of the human-mouse chimeric ch14.18 monoclonal antibody (dinutuximab beta) targeting GD2, a disialoganglioside which is abundantly expressed on tumor cells of neuroectodermal origin, combined with granulocyte-macrophage colony-stimulating factor and interleukin 2 (IL2) improved two-year event-free survival (EFS) and OS of patients in the situation of minimal residual disease by 20% and 11%, respectively (7–9).